

User fees or equity funds in low-income countries

See [Viewpoint](#)
Lancet 2006; **368**: 2253–57

In last week's *Lancet*, Bruno Meessen and colleagues¹ compared fundamentally different approaches to redress the unfairness towards poor individuals that characterises health systems in low-income countries: equity funds and abolition of user fees. In Cambodia, an equity fund was established to enable the poorest patients in hospitals to be exempted from health-care and transport fees. By contrast, user fees in Uganda were abolished at all levels of the health system for all patients.

Both experiments sharply increased attendance by poor patients. Two crucial differences merit discussion. First, the Cambodian system recognised that financial barriers in health-care access include indirect costs such as transport or opportunity costs. By only abolishing user fees, the Ugandan experiment neglected this point. Transport as a proportion of total patients' costs can be high,² especially in developing countries (28% in

Burkina Faso, 25% in northeast Brazil). In Tanzania, costs of transport were so high that "the substantial costs in time and effort and the money spent on travel make it unjustifiable to introduce charges on the grounds that it would discourage frivolous use of services".³ Thus the abolition of user fees does not resolve all financial barriers for poor patients. However, user fees are a major part of the reason why the poorest groups are excluded from health care, and alternatives need to be found.

Second, use of performance-based payment in Cambodia is increasingly advocated by donors such as the World Bank to improve health-care delivery. Performance-based payment has been praised for overcoming the limitations of per-capita fees (leading to under-provision of services) and fees for services (leading to over-provision of services). Meessen and colleagues point out that the removal of user fees in Uganda removed the incentive for providers to aim for quality care. This observation assumes that patients can influence quality of providers through payment. The fundamental question is why such financial incentives should come from patients, especially from those least able to pay. Since Meessen and colleagues, among many others, accept that user fees are regressive, discussion of other funding mechanisms to support incentives, such as capitation, would be useful.

Meessen and colleagues' article sits at a crucial moment in the debate about access to health care for poor people in low-income countries. Donors and health economists have advocated user fees since the 1980s as a sustainable and cost-effective health-financing mechanism able to constrain health-care demand in resource-scarce countries.⁴ Individual studies claiming to show benefits of user fees, such as curtailing frivolous demand for health care,⁵ encouraging individuals to take responsibility for their health (including preventive behaviour),⁶ and reducing inappropriate use of referrals,⁷ have been repeatedly contradicted. Rice and Morrison⁸ and Sepehri and Chermonas,⁹ among others, have shown that problems with efficiency and equity persist with user fees. User fees are not always cost effective: national systems have generated an average of only 5% of total recurrent health-system expenditure,¹⁰ and necessary as well as unnecessary demand for care is constrained. The RAND Health Experiment—a large

The printed journal
 includes an image merely
 for illustration

Still Pictures

Field hospital in Burkina Faso

randomised study in the 1970s in the USA—showed that health-service use fell as cost-sharing increased. However, there were reductions in both ineffective and effective services, and poorer health outcomes overall.¹¹ Also, supply-side incentives (ie, for health workers) might be more efficient at constraining demand than demand-side incentives (ie, for patients).¹² For equity, because health care has been argued to be an essential good, the demand for it will not fall with price (ie, price inelasticity), and people in the lowest income quintile have shown to be highly responsive to even small changes in price.¹³ Hence, even very small fees can reduce their access, and exemption mechanisms for these groups have repeatedly failed.⁹ Médecins Sans Frontières studied prices paid in several sub-Saharan African countries at public-health centres that applied user fees for primary care,^{14–16} and found that the fees represented a substantial share of household expenditure (equivalent to 12–30 days of expenses), forcing many families to borrow money or sell goods.

All this information begs the question of why we still need to argue about user fees. The discussion is an old one,¹⁷ but unfortunately still relevant. The debate has regained intensity in view of the international agenda for poverty alleviation and the Millennium Development Goals, and Meessen and colleagues' article is a useful addition. Several donors have acknowledged the failings of user fees, some at least rhetorically (World Bank), and others are adapting their aid-policy implementation (UK Department for International Development). Some countries have recently abolished user fees fully (Uganda, Zambia) or partly (Burundi, Niger). Yet, user fees remain in most of sub-Saharan Africa, often publicly denounced by donors but privately accepted as the only viable option if poor countries are not to spend more than their domestic resources allow.

Health economists and donors are now focusing on community-based health insurance, which is defined as any scheme with voluntary membership that uses prepayment for health care by community members.¹⁸ However, the fundamental question remains—who will pay for those unable to afford it?

Meessen and colleagues rightly conclude that no one solution can improve access for poor individuals

worldwide. However, they point out that context-specific solutions are attainable. It is time to learn from the accumulated evidence from the past two decades and follow up with action to effectively overcome financial barriers for the world's poorest populations.

*Nouria Brikci, Mit Philips

Programmes' Unit, Médecins Sans Frontières, London EC1N 8QX, UK (NB); and Médecins Sans Frontières, Brussels, Belgium (MP)
nouria.brikci@london.msf.org

The views expressed in this Comment are our own and do not necessarily reflect those of MSF. We thank Sarah Venis for help in the preparation of this Comment. We declare that we have no conflict of interest.

- 1 Meessen B, Van Damme W, Kirunga Tashobya CK, Tibouti A. Poverty and user fees for public health care in low-income countries: lessons from Uganda and Cambodia. *Lancet* 2006; **368**: 2253–57.
- 2 Ensor T, Cooper S. Overcoming barriers to health service access: influencing the demand side. *Health Policy Plan* 2004; **19**: 69–79.
- 3 Abel-Smith B, Rawal P. Can the poor afford 'free' health services? A case study of Tanzania. *Health Policy Plan* 1992; **7**: 4.
- 4 Shaw RP, Griffin CC. Financing health-care in sub-Saharan Africa through user fees and insurance. Washington, DC: Directions in Development, World Bank, 1995.
- 5 Griffin C. User charges for health care in principle and practice. EDI seminar paper no 37. Washington DC: World Bank, 1987.
- 6 Atkin J, Griffin C, Guilkey D, Popkin B. The demand for adult outpatient services in the Bicol region of the Philippines. *Soc Sci Med* 1986; **22**: 321–27.
- 7 Kutzin J. The appropriate role for patient cost sharing. In: Saltman R, Figueras J, Sakellarides C, eds. *Critical challenges for health care reform in Europe*. Buckingham, UK: Open University Press, 1998.
- 8 Rice T, Morrison KR. Patient cost sharing for medical services: a review of the literature and implications for health care reform. *Med Care Rev* 1994; **51**: 235–87.
- 9 Sepehri A, Chermonas R. Are user charges efficiency- and equity-enhancing? A critical review of economic literature with particular reference to experience from developing countries. *J Int Dev* 2001; **13**: 183–209.
- 10 Gilson L. The lessons of user fee experience in Africa. *Health Policy Plan* 1997; **12**: 273–85.
- 11 Robinson R. User charges for health care. In: Mossialos E, Dixon A, Figueras J, Kutzin J, eds. *Funding health care: options for Europe*. Buckingham, UK: Open University Press, 2002.
- 12 Kutzin J. The appropriate role for patient cost sharing. In: Saltman R, Figueras J, Sakellarides C, eds. *Critical challenges for health care reform in Europe*. Buckingham, UK: Open University Press, 1998.
- 13 Gertler P, Locay L, Sanderson W. Are user fees regressive? *J Econometrics* 1987; **36**: 67–88.
- 14 Kassa A, Van Herp M, Philips M, Ponsar F. Accès aux soins, mortalité et violence en République Démocratique du Congo. 2005: http://193.91.99.34/pdf/drc_acces_fr.pdf (accessed Nov 24, 2006).
- 15 MSB Belgium. Accès aux soins de santé au Burundi—résultats de trois enquêtes épidémiologiques. 2004: http://www.msf.be/fr/pdf/burundi_fr.pdf (accessed Nov 24, 2006).
- 16 MSB Belgium. Access to healthcare in post-war Sierra Leone—summary of a 2005 survey in four districts: Kambia, Tonkolili, Bombali, Bo. 2006: http://www.msf.be/nl/pdf/sierraleone_rapport_summary.pdf (accessed Nov 24, 2006).
- 17 Perin I, Attaran A. Trading ideology for dialogue: an opportunity to fix international aid for health? *Lancet* 2003; **361**: 1216–19.
- 18 Hsiao WC. Unmet health needs of two billion—is community financing a solution? HNP discussion paper, September, 2001. Washington, DC: World Bank, 2001.